In the rapidly evolving field of regenerative medicine, REPROCELL’s StemRNATM Clinical iPSCs provide a benchmark for clinical grade induced pluripotent stem cells (iPSCs). These high-quality iPSCs provide a foundation for various cell therapy programs, ensuring safety, consistency, and regulatory compliance. Our clinical iPSCs are currently being evaluated by many biopharma companies globally, are selected for regulatory filings and are IND approved. REPROCELL is a trusted partner for cell therapy developers who are seeking robust, high-quality clinical iPSC banks that meet industry standards. [Read more…]
REPROCELL’s Clinical-Grade iPSCs:
Unlocking the Power of iPSCs: iPSC Product Categories and their Importance
Since their discovery in 2006, induced pluripotent stem cells (iPSCs) have revolutionized research practices, offering a novel tool for studying diseases, testing drugs, exploring toxicities, and advancing regenerative medicine therapies. These stem cells are derived from adult somatic cells and reprogrammed to become pluripotent, meaning they have the ability to differentiate into any type of cell in the body. The wide array of applications for iPSCs has led to a growing demand for specialized products to support their reprogramming, culture, engineering, differentiation, and analysis.
In this article, we will delve into the key product categories that facilitate iPSC research and their crucial roles in advancing this field. [Read more…]
Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development
MONT-SAINT-GUIBERT, Belgium — Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, announces the launch of its Allo Chassis™—ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cell primary cells. These innovative cell lines represent a substantial leap forward in cell line development, effectively reducing both timelines and costs. Leveraging Cellistic’s extensive expertise in iPSCs, including in the development of T-cell based treatments, the Allo Chassis™ cell lines set a new standard in the cell therapy market with their unprecedented technology, developed in accordance with current Good Manufacturing Practice (cGMP) standards. [Read more…]
Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials
AUSTIN, Texas — Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Fertilo, to enable the launch of the first US-based Phase 3 clinical trial for an induced pluripotent stem cell (iPSC)-based therapy. This groundbreaking milestone highlights the potential of iPSC technology to address critical unmet needs in reproductive medicine. [Read more…]
Ncardia launches Ncyte® Heart in a Box
LEIDEN, THE NETHERLANDS, February 6, 2025 – Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery.
The Ncyte® Heart in a Box system is derived from hiPSC and integrates three essential cardiac cell types: ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts. Together, these high-purity components form a physiologically relevant microtissue that replicates the complexity and functionality of the human heart. [Read more…]
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 79
- Next Page »